- Women’s Gymnastics Brings High Risk for Concussion
- Move to ‘Zero-Emission’ Vehicles Would Save 90,000 U.S. Lives by 2050
- Smoke From Canadian Wildfires Blackens Skies, Prompts Air Quality Alerts in Much of U.S.
- FDA Finalizes Limit on How Much Arsenic Can Be in Apple Juice
- As Medical Debt Rises, So Do Cancer Death Rates
- Patients With Bladder Cancer May Avoid Removal of Extra Lymph Nodes, Study Finds
- Your Risk of COVID-Linked Smell Loss Is Much Lower Now: Study
- Going Solo: Masturbation May Give Humans an Evolutionary Edge
- Kids With ADHD, Behavior Issues Have Poorer Trajectories as Adults
- Gene-Targeted Drug Tagrisso Cuts Death Rate in Half for Patients With Early-Stage Lung Cancer
Generic Aciphex Approved to Treat Chronic Heartburn

FRIDAY, Nov. 8The first generic versions of the anti-GERD drug Aciphex (rabeprazole sodium) have been approved by the U.S. Food and Drug Administration for people aged 12 and older, the agency said Friday.
Gastroesophageal reflux disease (GERD), also known as chronic heartburn, is a very common disorder characterized by backward flow of stomach acid to the esophagus. This process could damage tissue in the esophagus, the tube that connects the throat and stomach.
License to produce generic rabeprazole was granted to Dr. Reddy’s Laboratories, Kremers Urban Pharmaceuticals, Lupin Pharmaceuticals, Mylan Pharmaceuticals, Teva Pharmaceuticals and Torrent Pharmaceuticals, the FDA said.
The drug is among a class called proton-pump inhibitors, which are designed to reduce the amount of stomach acid produced. Generic drugs, the FDA stressed, are equivalent to the brand-name versions in strength and quality.
More information
To learn more about GERD, visit Medline Plus.
Source: HealthDay
Copyright © 2023 HealthDay. All rights reserved.